Ingredion Incorporated
Ingredion Incorporated Declares Quarterly Dividend of $0.82 Per Share
Ingredion Incorporated Declares Quarterly Dividend of $0.82 Per Share
WESTCHESTER, Ill., Dec. 12, 2025 (GLOBE NEWSWIRE) -- Ingredion Incorporated (NYSE: INGR), a leading global provider of ingredient solutions, announced today that its board of directors has declared a quarterly dividend of $0.82 per share on the Company’s common stock. The quarterly dividend will be payable on Jan. 20, 2026, to stockholders of record at the close of business on Jan. 2, 2026.
For additional information about Ingredion Incorporated, including investor relations, financial updates, and upcoming announcements, visit https://ir.ingredionincorporated.com/.
ABOUT THE COMPANY
Ingredion Incorporated (NYSE: INGR) headquartered in the suburbs of Chicago, is a leading global ingredient solutions provider serving customers in more than 120 countries. With 2024 annual net sales of approximately $7.4 billion, the company turns grains, fruits, vegetables, and other plant-based materials into value-added ingredient solutions for the food, beverage, animal nutrition, brewing and industrial markets. With Ingredion's Idea Labs® innovation centers around the world and more than 11,000 employees, the company co-creates with customers and fulfills its purpose of bringing the potential of people, nature, and technology together to make life better. Visit ingredion.com for more information and the latest company news.
CONTACT:
Investors: Noah Weiss, 773-896-5242
Media: Rick Wion, 708-209-6323
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Verkkokauppa.com Oyj21.1.2026 13:00:00 CET | Press release
Verkkokauppa.com Oyj strengthens its management team and appoints Juha Valtonen as Chief Commercial Officer
Genmab A/S21.1.2026 12:23:17 CET | Press release
Genmab Announces Net Sales of DARZALEX® (daratumumab) for 2025
Comphya SA21.1.2026 12:00:00 CET | Press release
Comphya Announces Publication of CaverSTIM First-in-Man Clinical Study in BJUI and Scientific Review in Nature Urology
Rias A/S21.1.2026 11:48:16 CET | Press release
Interim Report - RIAS A/S
Rias A/S21.1.2026 11:48:16 CET | Pressemeddelelse
Periodemeddelelse - RIAS A/S
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom